AstraZeneca Results Presentation Deck

Emerging Markets -9M 2023 Total Revenue +10% at CER to $9.2bn, +20% at CER ex-COVID-19 medicines Total Revenue ($m) 4,000 3,500 3,000 2,500 2,000 1,500 1,000 500 0 Q3 2021 Q4 Q1 China Emerging Markets ex-China COVID-19 medicines 38 Growth at CER. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. CER = constant exchange rates; EM = Emerging Markets. Q2 2022 Q3 Q4 |||| Q1 APPENDIX | Emerging Markets Q2 2023 Q3 3

View entire presentation